Currently, prostate cancer is diagnosed in early stages by elevated serum prostate-specific antigen (PSA) levels, by clinical symptoms, and by imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT) and transrectal ultrasound, and finally confirmed by prostate biopsy. This evidence concerns the gene KLK3 and prostate carcinoma.